BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer. 1997;75:903-909. [PMID: 9062414 DOI: 10.1038/bjc.1997.159] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Sugiyama Y, Kato T, Nakazato H, Ito K, Mizuno I, Kanemitsu T, Matsumoto K, Yamaguchi A, Nakai K, Inada K, Tatematsu M. Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer. Anticancer Drugs 2002;13:931-8. [PMID: 12394256 DOI: 10.1097/00001813-200210000-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
2 Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009;32:38-43. [PMID: 19194123 DOI: 10.1097/coc.0b013e31817be58e] [Cited by in Crossref: 74] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
3 Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis. 2004;19:23-42. [PMID: 12827409 DOI: 10.1007/s00384-003-0499-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
4 Stoehlmacher J, Lenz H. Implications of Genetic Testing in the Management of Colorectal Cancer: . American Journal of PharmacoGenomics 2003;3:73-88. [DOI: 10.2165/00129785-200303020-00001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
5 Vincenzi B, Cesa AL, Santini D, Schiavon G, Grilli C, Graziano F, Tonini G. Predictive factors for response to chemotherapy in colorectal cancer patients. Crit Rev Oncol Hematol 2004;52:45-60. [PMID: 15363466 DOI: 10.1016/j.critrevonc.2004.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
6 Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, Martini M, Barone C. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer. 2002;38:527-534. [PMID: 11872345 DOI: 10.1016/s0959-8049(01)00402-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
7 Jensen SA, Vainer B, Sørensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer. 2007;120:694-701. [PMID: 17096352 DOI: 10.1002/ijc.22318] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
8 Aschele C, Lonardi S, Monfardini S. Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treatment Reviews 2002;28:27-47. [DOI: 10.1053/ctrv.2002.0253] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
9 Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother 2004;16 Suppl 4:25-30. [PMID: 15688605 DOI: 10.1179/joc.2004.16.Supplement-1.25] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529-536. [PMID: 14752076 DOI: 10.1200/jco.2004.05.064] [Cited by in Crossref: 338] [Cited by in F6Publishing: 109] [Article Influence: 19.9] [Reference Citation Analysis]
11 Webley SD, Hardcastle A, Ladner RD, Jackman AL, Aherne GW. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer 2000;83:792-9. [PMID: 10952785 DOI: 10.1054/bjoc.2000.1358] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
12 Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T, Yonezawa H, Oyama K, Saito K, Kanzaki N. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer. 2003;6 Suppl 1:71-81. [PMID: 12775024 DOI: 10.1007/s10120-003-0221-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
13 Etienne M, Chazal M, Laurent-puig P, Magné N, Rosty C, Formento J, Francoual M, Formento P, Renée N, Chamorey E, Bourgeon A, Seitz J, Delpero J, Letoublon C, Pezet D, Milano G. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses. JCO 2002;20:2832-43. [DOI: 10.1200/jco.2002.09.091] [Cited by in Crossref: 142] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
14 Wong NA, Brett L, Stewart M, Leitch A, Longley DB, Dunlop MG, Johnston PG, Lessells AM, Jodrell DI. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer. 2001;85:1937-1943. [PMID: 11747337 DOI: 10.1054/bjoc.2001.2175] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
15 van Heek NT, Clayton SJ, Sturm PD, Walker J, Gouma DJ, Noorduyn LA, Offerhaus GJ, Fox JC. Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. J Clin Pathol 2005;58:1315-20. [PMID: 16311354 DOI: 10.1136/jcp.2004.022707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
16 Peters GJ, Köhne CH. Fluoropyrimidines as Antifolate Drugs. In: Jackman AL, editor. Antifolate Drugs in Cancer Therapy. Totowa: Humana Press; 1999. pp. 101-45. [DOI: 10.1007/978-1-59259-725-3_5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
17 Seymour M. Colorectal cancer: treatment of advanced disease. Cancer Treatment Reviews 1998;24:119-31. [DOI: 10.1016/s0305-7372(98)90078-0] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
18 Mcdermott U, Longley D, Johnston P. Molecular and biochemical markers in colorectal cancer. Annals of Oncology 2002;13:235-45. [DOI: 10.1093/annonc/mdf665] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
19 Zhang Y, Ma J, Zhang S, Deng G, Wu X, He J, Pei H, Shen H, Zeng S. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis 2015;30:1173-83. [PMID: 26054387 DOI: 10.1007/s00384-015-2273-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
20 Ahmed FE. Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn. 2005;5:353-375. [PMID: 15934813 DOI: 10.1586/14737159.5.3.353] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
21 Beale P, Clarke S. Tomudex. In: Jackman AL, editor. Antifolate Drugs in Cancer Therapy. Totowa: Humana Press; 1999. pp. 167-81. [DOI: 10.1007/978-1-59259-725-3_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Calascibetta A, Contino F, Feo S, Gulotta G, Cajozzo M, Antona A, Sanguedolce G, Sanguedolce R. Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response. J Nucleic Acids 2010;2010:306754. [PMID: 20725619 DOI: 10.4061/2010/306754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Kristensen MH, Weidinger M, Bzorek M, Pedersen PL, Mejer J. Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. J Int Med Res 2010;38:484-97. [PMID: 20515563 DOI: 10.1177/147323001003800212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
24 Haqqani AS, Cowling RT, Maroun JA, Birnboim HC. Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens. J Histochem Cytochem 1999;47:1563-74. [PMID: 10567440 DOI: 10.1177/002215549904701208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kornmann M, Hebart H, Danenberg K, Goeb R, Staib L, Kron M, Henne-bruns D, Danenberg P, Link K. Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomised multicentre trial. European Journal of Cancer 2012;48:1443-51. [DOI: 10.1016/j.ejca.2011.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Longley DB, Mcdermott U, Johnston PG. Clinical significance of prognostic and predictive markers in colorectal cancer. Pharmacogenomics J 2002;2:209-16. [DOI: 10.1038/sj.tpj.6500124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
27 Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, Guo Y, Huang Y, Tian Y, Xie D, Zhang L. Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. Onco Targets Ther 2014;7:1301-10. [PMID: 25114572 DOI: 10.2147/OTT.S65067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
28 Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A, Zoli W, Scarpi E, Turci D, Oliverio G, Gambi A, Amadori D. Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 2002;87:868-75. [PMID: 12373601 DOI: 10.1038/sj.bjc.6600569] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
29 Van Triest B, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P, Telleman F, Tadema T, Aherne GW, Van Groeningen CJ, Zoetmulder FA, Taal BG, Johnston PG, Peters GJ. Thymidylate Synthase Expression in Patients with Colorectal Carcinoma Using a Polyclonal Thymidylate Synthase Antibody in Comparison to the TS 106 Monoclonal Antibody. J Histochem Cytochem 2000;48:755-60. [DOI: 10.1177/002215540004800604] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
30 Peters GJ, Smid K, Meijer E, van Groeningen CJ, Leon LG. Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil. Nucleosides Nucleotides Nucleic Acids 2016;35:595-603. [PMID: 27906628 DOI: 10.1080/15257770.2016.1218020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Longley DB, Mcdermott U, Johnston PG. Predictive Markers for Colorectal Cancer: Current Status and Future Prospects. Clinical Colorectal Cancer 2003;2:223-30. [DOI: 10.3816/ccc.2003.n.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Mader RM, Müller M, Steger GG. Resistance to 5-Fluorouracil. General Pharmacology: The Vascular System 1998;31:661-6. [DOI: 10.1016/s0306-3623(98)00191-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
33 Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J. 2011;17:114-126. [PMID: 21427555 DOI: 10.1097/ppo.0b013e318212f844] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
34 Kawasaki G, Yoshitomi I, Yanamoto S, Mizuno A. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: An immunohistochemical and clinicopathologic study. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2002;94:717-23. [DOI: 10.1067/moe.2002.126912] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
35 Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, Shao Y, Aherne W, Houlston R. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol. 2006;17:1810-1817. [PMID: 16971666 DOI: 10.1093/annonc/mdl301] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
36 Smorenburg C, Peters G, van Groeningen C, Noordhuis P, Smid K, van Riel A, Dercksen W, Pinedo H, Giaccone G. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Annals of Oncology 2006;17:35-42. [DOI: 10.1093/annonc/mdj046] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
37 Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A. Immunohistochemical Quantitation of Thymidylate Synthase Expression in Colorectal Cancer Metastases Predicts for Clinical Outcome to Fluorouracil-Based Chemotherapy. JCO 1999;17:1760-1760. [DOI: 10.1200/jco.1999.17.6.1760] [Cited by in Crossref: 142] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
38 Marsh S. Concordance Between Tumor and Germline DNA. In: Innocenti F, editor. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Totowa: Humana Press; 2009. pp. 91-101. [DOI: 10.1007/978-1-60327-088-5_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Wang TL, Diaz LA Jr, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004;101:3089-3094. [PMID: 14970324 DOI: 10.1073/pnas.0308716101] [Cited by in Crossref: 129] [Cited by in F6Publishing: 104] [Article Influence: 7.6] [Reference Citation Analysis]
40 Allegra C. Thymidylate Synthase Levels: Prognostic, Predictive, or Both? JCO 2002;20:1711-3. [DOI: 10.1200/jco.2002.20.7.1711] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
41 Mariadason JM, Arango D, Augenlicht LH. Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resist Updat 2004;7:209-18. [PMID: 15296862 DOI: 10.1016/j.drup.2004.05.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
42 Qiu L, Tang Q, Bai J, Qian X, Li R, Liu B, Zheng M. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies. Int J Cancer 2008;123:2384-9. [DOI: 10.1002/ijc.23822] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
43 Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002;38:1000-15. [PMID: 11978525 DOI: 10.1016/s0959-8049(02)00062-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
44 Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta. 2006;1766:184-196. [PMID: 16973289 DOI: 10.1016/j.bbcan.2006.08.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 63] [Article Influence: 1.7] [Reference Citation Analysis]
45 López-Gómez M, Cejas P, Merino M, Fernández-Luengas D, Casado E, Feliu J. Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? Clin Transl Oncol 2012;14:641-58. [PMID: 22911546 DOI: 10.1007/s12094-012-0853-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
46 Yeh C, Chen W, Lin H, Chang T, Lin Y. Development of an immunoassay based on impedance measurements utilizing an antibody–nanosilver probe, silver enhancement, and electro-microchip. Sensors and Actuators B: Chemical 2009;139:387-93. [DOI: 10.1016/j.snb.2009.03.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
47 Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz H, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll H, Sobrero A, Tabernero J. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Annals of Oncology 2010;21:vi1-vi10. [DOI: 10.1093/annonc/mdq273] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
48 Moreira LR, Almeida Schenka A, Latuff Filho P, Nascimento H, Passos Lima CS, Silva Trevisan MA, Vassallo J. Correlation Between Thymidylate Synthase Protein Expression and Gene Polymorphism with Clinicopathological Parameters in Colorectal Carcinoma. Int J Surg Pathol 2009;17:181-6. [DOI: 10.1177/1066896908330480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer. 2001;37:1681-1687. [PMID: 11527696 DOI: 10.1016/S0959-8049(01)00174-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
50 Mirjolet J, Didelot C, Barberi-heyob M, Merlin J. G1/S but not G0/G1 cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002;48:6-13. [DOI: 10.1002/cyto.10087] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
51 De Mattos-Arruda L, Dienstmann R, Tabernero J. Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer. 2011;10:279-289. [PMID: 21729679 DOI: 10.1016/j.clcc.2011.03.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
52 Tan BR, Mcleod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Seminars in Oncology 2005;32:113-9. [DOI: 10.1053/j.seminoncol.2004.09.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
53 Lassmann S, Hennig M, Rosenberg R, Nährig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Höfler H, Werner M. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis. 2006;21:238-247. [PMID: 16132996 DOI: 10.1007/s00384-005-0767-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
54 Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. Anticancer Drugs. 2010;21:313-319. [PMID: 20016369 DOI: 10.1097/cad.0b013e328334d88a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Yamada H, Ichikawa W, Uetake H, Shirota Y, Nihei Z, Sugihara K, Hirayama R. Thymidylate Synthase Gene Expression in Primary Colorectal Cancer and Metastatic Sites. Clinical Colorectal Cancer 2001;1:169-73. [DOI: 10.3816/ccc.2001.n.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
56 Clayton SJ, Scott FM, Walker J, Callaghan K, Haque K, Liloglou T, Xinarianos G, Shawcross S, Ceuppens P, Field JK, Fox JC. K-ras Point Mutation Detection in Lung Cancer: Comparison of Two Approaches to Somatic Mutation Detection Using ARMS Allele-specific Amplification. Clinical Chemistry 2000;46:1929-38. [DOI: 10.1093/clinchem/46.12.1929] [Cited by in Crossref: 57] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
57 Scott N, Hale A, Deakin M, Hand P, Adab FA, Hall C, Williams GT, Elder JB. A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol. 1998;24:169-173. [PMID: 9630854 DOI: 10.1016/s0748-7983(98)92861-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
58 Catalano V, Baldelli AM, Giordani P, Cascinu S. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Critical Reviews in Oncology/Hematology 2001;38:93-104. [DOI: 10.1016/s1040-8428(00)00114-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
59 Johnston PG, Benson AB 3rd, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815-9. [PMID: 12610179 DOI: 10.1200/JCO.2003.07.039] [Cited by in Crossref: 66] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
60 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
61 McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191-203. [PMID: 9888457 DOI: 10.1038/sj.bjc.6690033] [Cited by in Crossref: 155] [Cited by in F6Publishing: 131] [Article Influence: 7.0] [Reference Citation Analysis]
62 Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer. 2000;82:560-567. [PMID: 10682666 DOI: 10.1054/bjoc.1999.0964] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 4.9] [Reference Citation Analysis]
63 Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, Bey P. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer. 1998;78:62-68. [PMID: 9662252 DOI: 10.1038/bjc.1998.443] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
64 Grem JL. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Seminars in Oncology 2005;32:120-7. [DOI: 10.1053/j.seminoncol.2004.09.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
65 McLeod HL, McKay JA, Collie-Duguid ES, Cassidy J. Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer. 2000;36:1706-1712. [PMID: 10959056 DOI: 10.1016/s0959-8049(00)00150-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
66 Leichman CG. Predictive and prognostic markers in gastrointestinal cancers. Curr Opin Oncol 2001;13:291-9. [PMID: 11429488 DOI: 10.1097/00001622-200107000-00013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
67 Formentini A, Henne-bruns D, Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 2004;389:405-13. [DOI: 10.1007/s00423-004-0510-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
68 Gajjar KK, Vora HH, Kobawala TP, Trivedi TI, Ghosh NR. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients. Int J Biol Markers 2018;33:180-8. [DOI: 10.1177/1724600817748539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
69 Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226-243. [PMID: 16041392 DOI: 10.1038/sj.tpj.6500320] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]